Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.

Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries.